Pegylated Drugs Market Research Report Information by Molecule (Macromolecular Drugs (Protein and Peptide, Enzyme, Aptamer), Small Molecular Drugs, Lipid Nanoparticles (LNP) and Liposomes), by Application (Oncology, Neurology, Autoimmune Diseases, Haematology, Others), by Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) and Region (North America, Europe, Asia-Pacific, Rest of the World) - Forecast till 2035

PEGylated Drugs Market Summary

As per MRFR Analysis, the PEGylated Drugs Market was valued at USD 7.41 Billion in 2023 and is projected to grow to USD 17.80 Billion by 2032, with a CAGR of 10.25% from 2024 to 2032. The market growth is driven by the rising prevalence of diseases such as cancer, advancements in biologics, and the increasing pharmaceutical industry. However, challenges such as drug side effects and failures may restrain growth. The market is segmented by molecule (e.g., proteins, enzymes) and indication (e.g., cancer, hepatitis). The cancer segment held a 60% market share in 2017, while the hepatitis segment is expected to grow at a CAGR of 12%. The Americas dominate the market with a 65.73% share in 2018, driven by high cancer rates in Canada and the U.S.

Key Market Trends & Highlights

The PEGylated Drugs Market is witnessing significant growth driven by various factors.

• Market Size in 2023: USD 7.41 Billion
• Projected Market Size by 2032: USD 17.80 Billion
• CAGR from 2024 to 2032: 10.25%
• Cancer segment held 60% market share in 2017

Market Size & Forecast

2023 Market Size: USD 7.41 Billion

2024 Market Size: USD 8.16 Billion

2032 Market Size: USD 17.80 Billion

CAGR (2024-2032): 10.25%

Major Players

Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Biogen, BioMarin Pharmaceutical Inc, Coherus BioSciences, Enzon, Leadiant Biosciences, Inc.

The increasing incidences of chronic diseases and advancements in biologics and recently approved Pegylated Drugs are driving the growth of the Pegylated Drugs Market.

As per the Analyst at MRFR, the increasing incidence of chronic diseases, such as cancer, autoimmune disorders, and cardiovascular diseases, is significantly driving the growth of the Pegylated Drugs Market. As these conditions become more prevalent worldwide, the demand for effective, long-term treatment options intensifies.

 FIGURE 1: PEGYLATED DRUGS MARKET VALUE (2019-2035) USD BILLION

 Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Pegylated Drugs Market Opportunity

EMERGING MARKETS

Expanding healthcare infrastructure in emerging markets is unlocking significant opportunities for the distribution and adoption of Pegylated Drugs, creating a new growth avenue for the Pegylated Drugs Market. As countries in regions like Asia-Pacific, Latin America, and the Middle East continue to invest in healthcare improvements, there is a growing demand for advanced treatments, including PEGylated therapies, which offer enhanced efficacy, prolonged half-life, and reduced immunogenicity. 

For instance, the World Health Organization reported in 2021, approximately 11% of the global population resided in countries that allocated less than USD 50 per person annually for healthcare, whereas high-income countries spent an average of USD 4,000 per capita on health. Despite representing 8% of the world’s population, low-income countries contributed just 0.24% of total global health expenditure.

This expanding infrastructure not only increases access to innovative drugs but also boosts the acceptance and integration of novel biologics into local treatment regimens. OECD, 2024, between 2015 and 2021, per capita health spending in low- and lower-middle-income Asia-Pacific countries increased by an average of 4.6% annually, while in upper-middle-income countries, it grew by 6% per year over the same period. In high-income countries within the region, health spending also saw growth, but at a slower rate of 3.5% per year. Additionally, as these markets see improvements in regulatory frameworks and healthcare financing, pharmaceutical companies are increasingly able to penetrate these regions, spurring competition and fostering innovation.

This trend is driving the Pegylated Drugs Market by opening up untapped markets, fostering strategic partnerships, and encouraging local manufacturing, ultimately contributing to the growth of the industry worldwide.

Pegylated Drugs Market Segment Insights

Pegylated Drugs by Molecule Insights

Based on Molecule, this segment includes Macromolecular Drugs (Protein and Peptide, Enzyme, Aptamer), Small Molecular Drugs, Lipid Nanoparticles (LNP) and Liposomes. The - Macromolecular Drugs segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period. Macromolecular Drugs Market is experiencing significant growth due to the increasing demand for biologics and long-acting therapeutics in treating chronic diseases such as cancer, hepatitis, and autoimmune disorders. 

PEGylation, the process of attaching polyethylene glycol (PEG) chains to macromolecules like proteins, peptides, and enzyme, enhances drug stability, reduces immunogenicity, and prolongs circulation time, leading to improved patient compliance. Key market drivers include advancements in PEGylation technology, the rising prevalence of infectious and chronic diseases, and increased investments in biopharmaceutical R&D. 

Leading pharmaceutical companies such as Merck & Co., Roche, Pfizer, Amgen, and Biogen are actively developing Pegylated Drugs, with Molecules like Pegfilgrastim (Neulasta), Peginterferon alfa-2a (Pegasys), and Pegloticase (Krystexxa) dominating the market. However, challenges such as the high cost of PEGylation processes, stringent regulatory requirements, and potential immunogenicity concerns could impact growth.

FIGURE 2: PEGYLATED DRUGS MARKET SHARE BY MOLECULE 2024 AND 2035 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Pegylated Drugs by Application Insights

Based on Application, this segment includes Oncology, Neurology, Autoimmune Diseases, Rare Haematology, Others. The Others segment dominated the global market in 2024, while the Oncology segment is projected to be the fastest–growing segment during the forecast period. Others include Hypoparathyroidism, Geographic Atrophy (GA), Fabry disease, Geographic Atrophy (GA), Growth Hormone Deficiency, Phenylketonuria, ADA-SCID, Macular Degeneration, Acromegaly, Hepatitis B and C, Hepatitis C, Melanoma, Constipation, Varicose Veins, Prevention of COVID-19, Prevention of COVID-19, ophthalmology, dermatology, etc. Gastroenterology, Infectious Diseases, Ophthalmology, and Dermatology Applications are experiencing significant growth due to advancements in drug delivery technologies and the rising prevalence of chronic diseases. 

In gastroenterology, Pegylated Drugs like PEG 3350-based laxatives are widely used for constipation treatment and bowel cleansing before medical procedures. In infectious diseases, PEGylated interferons such as Peginterferon alfa-2a and Peginterferon alfa-2b enhance drug stability and efficacy in managing hepatitis B and C. In ophthalmology, PEGylation improves drug delivery for age-related macular degeneration (AMD) and retinal diseases, prolonging therapeutic effects.

Pegylated Drugs by Distribution Channel Insights

Based on Distribution Channel, this segment includes Hospital Pharmacy, Online Pharmacy, Retail Pharmacy. The Hospital Pharmacy segment dominated the global market in 2024, while the Online Pharmacy segment is projected to be the fastest–growing segment during the forecast period. 

Hospital pharmacies are growing due to the increasing demand for targeted therapies with improved efficacy and reduced side effects. Hospital pharmacies are key distribution channels for the drugs, ensuring timely access to patients. Advances in biotechnology and favorable regulatory environments to support market expansion. As healthcare systems focus on personalized medicine, the demand for Pegylated Drugs in hospital settings is expected to rise, driving growth in this sector.

Pegylated Drugs Regional Insights

Based on the Region, the global Pegylated Drugs are segmented into North America, Europe, Asia-Pacific and Rest of the World. The North America dominated the global market in 2024, while the Asia-Pacific is projected to be the fastest–growing segment during the forecast period. Major demand factors driving the North America market are the increasing incidences of chronic diseases and advancements in biologics and recently approved Pegylated Drugs. 

The North America Pegylated Drugs market, encompassing the US and Canada, is witnessing robust growth, fueled by advancements in drug delivery systems and the rising demand for improved therapeutic outcomes. PEGylation, the process of attaching polyethylene glycol (PEG) to drugs, enhances their stability, reduces immunogenicity, and prolongs their half-life in the bloodstream. This technology has revolutionized the treatment of chronic diseases such as cancer, hepatitis, and autoimmune disorders, driving its adoption across the region.

FIGURE 3: PEGYLATED DRUGS MARKET VALUE BY REGION 2024 AND 2035 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Further, the countries considered in the scope of the Application Tracking System Market are the US, Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Australia, South Korea, Middle East and Africa, South America and others.

Global Pegylated Drugs Key Market Players & Competitive Insights

Many global, regional, and local vendors characterize the Pegylated Drugs Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.

The major competitors in the market are Amgen Inc., Pfizer Inc., Biogen, Bayer AG, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Sandoz Group Ag, AstraZeneca, Coherus BioSciences, Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson Inc., Alnylam Pharmaceuticals, Inc., LES Laboratoires Servier are among others. The Pegylated Drugs Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.

Key Companies in the Pegylated Drugs Market include

• Amgen Inc.
• Pfizer Inc.
• Biogen
• Bayer AG
• Takeda Pharmaceutical Company Limited
• Novo Nordisk A/S
• Sandoz Group Ag
• AstraZeneca
• Coherus BioSciences, Inc.
• Hoffmann-La Roche Ltd
• Johnson & Johnson Inc.
• Alnylam Pharmaceuticals, Inc.
• LES Laboratoires Servier

Pegylated Drugs Market Industry Developments

November 2024: Amgen presented new data from its rare disease portfolio and pipeline at the American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C. The AGILE trial evaluated the safety, tolerability, and efficacy of KRYSTEXXA administered with a shorter infusion duration in patients with uncontrolled gout who received methotrexate as co-administration.

December 2024: Coherus BioSciences, Inc. announced that it had entered into an asset purchase agreement (the Agreement) dated December 2, 2024, with Intas Pharmaceuticals Ltd. (Intas) for the divestiture of the UDENYCA (pegfilgrastim-cbqv) franchise for up to $558.4 million.

October 2023: The FDA declined to approve Alnylam's Onpattro in ATTR-CM. The judgment has no bearing on Onpattro's current indication for another type of ATTR known as polyneuropathy, which affects peripheral nerves.

February 2021: Biogen received FDA Approval of PLEGRIDY (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis.

Pegylated Drugs Market Segmentation

Pegylated Drugs by Molecule Outlook

• Macromolecular Drugs
  • Protein and Peptide
  • Enzyme
  • Aptamer
• Small Molecular Drugs
• Lipid Nanoparticles (LNP) and Liposomes

Pegylated Drugs by Application Outlook

• Oncology
• Neurology
• Autoimmune Diseases   
• Haematology
• Others

Pegylated Drugs by Distribution Channel Outlook

• Hospital Pharmacy     
• Online Pharmacy   
• Retail Pharmacy 

Pegylated Drugs Regional Outlook

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Rest of the World
  • Middle East and Africa
  • South America

Report Attribute/Metric	Details
Market Size 2024	USD 15.18 Billion
Market Size 2025	USD 16.00 Billion
Market Size 2035	USD 26.49 Billion
Compound Annual Growth Rate (CAGR)	5.17% (2025-2035)
Base Year	2024
Forecast Period	2025-2035
Historical Data	2019-2023
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Molecule, By Application, By Distribution Channel
Geographies Covered	North America, Europe, Asia Pacific, Rest of the World
Countries Covered	The US, Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Australia, South Korea, Middle East and Africa, South America
Key Companies Profiled	Amgen Inc., Pfizer Inc., Biogen, Bayer AG, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Sandoz Group Ag, AstraZeneca, Coherus BioSciences, Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson Inc., Alnylam Pharmaceuticals, Inc., LES Laboratoires Servier
Key Market Opportunities	·         Emerging markets ·         Innovative drug delivery systems ·         Personalized medicine
Key Market Dynamics	·         Increasing incidences of chronic diseases ·         Advancements in biology ·         Recently approved Pegylated Drugs